AMBROGIO, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 2.425
EU - Europa 1.685
AS - Asia 597
OC - Oceania 14
SA - Sud America 11
AF - Africa 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.740
Nazione #
US - Stati Uniti d'America 2.383
IT - Italia 449
CN - Cina 374
DK - Danimarca 222
SE - Svezia 216
IE - Irlanda 206
DE - Germania 125
UA - Ucraina 97
FR - Francia 90
AT - Austria 69
FI - Finlandia 63
IN - India 40
KR - Corea 40
VN - Vietnam 39
CA - Canada 36
JP - Giappone 35
GB - Regno Unito 33
PL - Polonia 30
ES - Italia 25
HK - Hong Kong 19
SG - Singapore 16
BE - Belgio 14
PT - Portogallo 13
AU - Australia 12
CH - Svizzera 8
TW - Taiwan 8
BR - Brasile 7
GR - Grecia 6
MX - Messico 5
MY - Malesia 5
TR - Turchia 5
SN - Senegal 4
MK - Macedonia 3
NL - Olanda 3
NO - Norvegia 3
PH - Filippine 3
AM - Armenia 2
AR - Argentina 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
IL - Israele 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
PE - Perù 2
RU - Federazione Russa 2
TH - Thailandia 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
DO - Repubblica Dominicana 1
EG - Egitto 1
EU - Europa 1
HU - Ungheria 1
ID - Indonesia 1
IR - Iran 1
KW - Kuwait 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
PK - Pakistan 1
RO - Romania 1
SA - Arabia Saudita 1
Totale 4.740
Città #
Ann Arbor 329
Chandler 324
Dublin 206
Beijing 200
Ashburn 160
Houston 128
Fairfield 120
Torino 113
Turin 87
Jacksonville 82
Wilmington 77
Nyköping 76
Vienna 67
Woodbridge 66
Cambridge 65
Princeton 53
Dearborn 45
Medford 43
Villeurbanne 43
Seattle 41
Boston 32
Shanghai 32
Dong Ket 29
Fremont 27
Warsaw 26
Milan 24
Pisa 24
Redwood City 22
Hangzhou 19
Boardman 16
Brussels 13
Grafing 13
Rome 13
San Diego 13
Tokyo 12
Washington 12
Falls Church 11
Guangzhou 11
New York 11
Chengdu 10
Madrid 10
Occimiano 10
Dallas 9
Hefei 9
Los Angeles 9
Trento 9
Aprilia 8
Munich 8
Ottawa 8
Pune 8
Central District 7
Nanjing 7
Norwalk 7
San Mateo 7
Singapore 7
Chennai 6
Chicago 6
Genoa 6
Montréal 6
Paris 6
El Paso 5
Helsinki 5
Kunming 5
Lissone 5
Nürnberg 5
San Jose 5
Saskatoon 5
Seoul 5
Toronto 5
Trieste 5
Bologna 4
Central 4
Düsseldorf 4
Edison 4
Hyderabad 4
Manchester 4
New Haven 4
Palaiseau 4
Pordenone 4
Raritan 4
Silver Spring 4
Verona 4
Wuhan 4
Alvaro Obregon 3
Aurora 3
Baotou 3
Barcelona 3
Bari 3
Berlin 3
Bochum 3
Buffalo 3
Cafasse 3
Changsha 3
Chongqing 3
Detroit 3
Frankfurt am Main 3
Guiyang 3
Göttingen 3
Hebei 3
Istanbul 3
Totale 3.001
Nome #
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells 359
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 240
Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma 235
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 231
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 223
KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer 221
Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin 210
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 202
Redundant and non-redundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice 180
The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1. 118
Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. 98
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 98
The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinase 91
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer 84
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination 83
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas 82
PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN. 82
ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis 81
Molecola perturbation of IFNγR2 internalization reinstates T cell sensitività to the IFNγ/STAT1 signaling pathway in vitro and in vivo. 5th 78
Expression of IFNgammaR2 mutated in a dileucine internalization motif reinstates IFNgamma signaling and apoptosis in human T lymphocytes 78
Discoveries in the redox regulation of KRAS 76
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 72
Human Wrnip1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner 71
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA 69
Increased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice 69
ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer 69
A Braf kinase-inactive mutant induces lung adenocarcinoma 68
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 67
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer 62
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 62
Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage 61
A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance 58
The anaplastic lymphoma kinase in the pathogenesis of cancer 57
Selective Therapeutic Targeting of the Anaplastic Lymphoma Kinase With Liposomal siRNA Induces Apoptosis and Inhibits Angiogenesis in Neuroblastoma. 57
Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma 57
Lentiviral-based approach for the validation of cancer therapeutic targets in vivo 54
Docking Protein p130Cas Regulates Acinar to Ductal Metaplasia During Pancreatic Adenocarcinoma Development and Pancreatitis 54
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer 53
TTC3 protein inhibits neuronal differentiation through RhoA and CITRON dependent mechanism 52
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma 52
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC) 51
Simple and Rapid InVivo Generation of Chromosomal Rearrangements using CRISPR/Cas9 Technology 48
MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. 43
Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts 40
Assessing therapeutic efficacy of MEK inhibition in a KrasG12C-driven mouse model of lung cancer 40
TTC3 protein inhibits neuronal differentiation through a RhoA dependent mechanism 39
Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer 39
The Tyrosine Phosphatase SHP2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. 37
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS 37
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer 30
YAP and TAZ orchestrate adaptive resistance to KRAS inhibitors 28
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer 28
The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers 23
A structural model of a Ras–Raf signalosome 21
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer 18
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain Metastases 14
A LIBRETTO to orchestrate targeted therapy 11
Cancer Hallmarks: Piecing the Puzzle Together 11
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node 9
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 8
The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer 8
Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma 8
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells 7
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer 5
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models 1
Exploiting signaling rewiring in cancer cells with co-existing oncogenic drivers 1
Totale 4.919
Categoria #
all - tutte 13.319
article - articoli 0
book - libri 0
conference - conferenze 645
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.964


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019117 0 0 0 0 0 0 0 0 0 31 56 30
2019/2020780 12 28 45 53 64 109 84 63 101 78 76 67
2020/2021689 68 40 70 23 81 30 41 31 70 73 66 96
2021/2022922 80 56 49 67 47 46 58 63 55 75 202 124
2022/20231.084 122 106 25 103 82 278 95 59 95 35 42 42
2023/2024508 59 77 40 59 45 112 29 47 4 36 0 0
Totale 4.919